Venture Capital Investment in the Life Sciences in Switzerland

Authors

  • Markus Hosang BioMedPartners AG Elisabethenstrasse 23 CH-4051 Basel, Switzerland. hosang@biomedvc.com

DOI:

https://doi.org/10.2533/chimia.2014.847

Keywords:

Biotechnology, Life sciences, Venture capital, Zukunftsfonds schweiz

Abstract

Innovation is one of the main driving factors for continuous and healthy economic growth and welfare. Switzerland as a resource-poor country is particularly dependent on innovation, and the life sciences, which comprise biotechnologies, (bio)pharmaceuticals, medical technologies and diagnostics, are one of the key areas of innovative strength of Switzerland. Venture capital financing and venture capitalists (frequently called 'VCs') and investors in public equities have played and still play a pivotal role in financing the Swiss biotechnology industry. In the following some general features of venture capital investment in life sciences as well as some opportunities and challenges which venture capital investors in Switzerland are facing are highlighted. In addition certain means to counteract these challenges including the 'Zukunftsfonds Schweiz' are discussed.

Downloads

Published

2014-12-17

How to Cite

[1]
M. Hosang, Chimia 2014, 68, 847, DOI: 10.2533/chimia.2014.847.